An interview with Professor Yohann Loriot (medical oncologist, Gustave Roussy Cancer Campus, Grand Paris, France) and Professor Emmanuel Seront (medical oncologist, Cliniques universitaires Saint-Luc, Brussels, Belgium) discussing the latest developments in the treatment of metastatic urothelial carcinoma (mUC), FGFR3 alterations, the THOR trial, and the use of Balversa (erdafitinib) in patients with FGFR3-positive mUC.